In contrast, the MAC score of patients without a GATA2 deficiency did not show any notable change with disease progression (MAC score mean ± SD in MDS-EB of 0.8686 ± 0.6336 versus 0.7621 ± 0.4522 in RCC). This evidence concerns the gene GATA2 and myelodysplastic syndrome.